Back to Search
Start Over
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.
- Source :
-
American journal of hematology [Am J Hematol] 2014 Oct; Vol. 89 (10), pp. 964-8. Date of Electronic Publication: 2014 Jul 21. - Publication Year :
- 2014
-
Abstract
- Despite being considered "good-risk" acute myelogenous leukemia (AML), long term outcomes in core binding factor (CBF) AML suggest room for improvement. We report on a regimen consisting of fludarabine, cytarabine, granulocyte colony stimulating factor, and low dose gemtuzumab ozogamicin (FLAG-GO) as front-line therapy of patients with CBF AML. Forty-five patients were enrolled (median age 48 years). Remission rate was 95% with 5% induction deaths. The overall survival (OS) and relapse free survival (RFS) probability at 3 years are 78% and 85%, respectively. FLAG-GO regimen results in high rates of RFS and OS in CBF AML. Our data along with recent data from several large groups strongly argues in favor of incorporation of gemtuzumab ozogamicin in frontline regimens for CBF AML.<br /> (© 2014 Wiley Periodicals, Inc.)
- Subjects :
- Adult
Aged
Aminoglycosides administration & dosage
Aminoglycosides adverse effects
Antibodies, Monoclonal, Humanized administration & dosage
Antibodies, Monoclonal, Humanized adverse effects
Antineoplastic Combined Chemotherapy Protocols adverse effects
Cytarabine administration & dosage
Cytarabine adverse effects
Disease-Free Survival
Female
Gemtuzumab
Granulocyte-Macrophage Colony-Stimulating Factor administration & dosage
Granulocyte-Macrophage Colony-Stimulating Factor adverse effects
Humans
Leukemia, Myeloid, Acute genetics
Leukemia, Myeloid, Acute mortality
Male
Middle Aged
Survival Rate
Vidarabine administration & dosage
Vidarabine adverse effects
Vidarabine analogs & derivatives
Antineoplastic Combined Chemotherapy Protocols administration & dosage
Core Binding Factors
Leukemia, Myeloid, Acute drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1096-8652
- Volume :
- 89
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- American journal of hematology
- Publication Type :
- Academic Journal
- Accession number :
- 24990142
- Full Text :
- https://doi.org/10.1002/ajh.23795